Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 21, 2021 07:15 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

SAN FRANCISCO, CA and TORONTO, ON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...
December 20, 2021 07:15 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

SAN FRANCISCO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that the...
November 18, 2021 07:15 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Provides Update Regarding Phase 1 Clinical Study

SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today provided an update regarding the...
November 04, 2021 07:15 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB

SAN FRANCISCO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") today announced the engagement of B....
October 19, 2021 07:15 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") is pleased to announce that it has closed the first...
September 16, 2021 07:15 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

SAN FRANCISCO and TORONTO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") today announced that it has entered...
August 18, 2021 12:52 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107

SAN FRANCISCO and TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTD) (the "Company" or "Claritas") is pleased to announce that, subject to...
July 27, 2021 19:55 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Announces Grant of Stock Options to Directors and Officers

SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") announced that it granted stock options on...
July 26, 2021 07:15 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107

SAN FRANCISCO and TORONTO, July 26, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that a recently published...
July 21, 2021 07:15 ET | Source: Claritas Pharmaceuticals, Inc.

Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease

SAN FRANCISCO and TORONTO, July 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to provide additional detail...